Date: October 26-29, 2020
Location: Virtual Conference
Virtual Booth: Catalent
Region President, Europe, Catalent Biologics
Session Title: How COVID-19 is Bending the Curve on Vaccine Development and Manufacturing Norms
Date/Time: Available on-demand beginning October 26, 2020
Abstract: Catalent announced its acquisition of the Anagni, Italy site from Bristol-Myers Squibb in June 2019 to enhance its late-stage and commercial capabilities for biologics, sterile injectables and oral solid dose products in Europe. As the COVID-19 virus began to spread into a global pandemic, the site quickly pivoted its efforts to support manufacturing hundreds of millions of doses of COVID-19 vaccine candidates in Europe.
In this interview, hear Mario Gargiulo, Catalent’s Region President, Biologics, Europe describe the accelerated timelines and activities required to produce COVID-19 vaccine and therapeutic candidates in Anagni and our other global biologic sites.